Peptide Biologix
Compound index
The atlas

Hexarelin Technical Specification Sheet

GH / GHRH Axis · MW 887.04 g/mol · Examorelin · Methylated GHRP-6 analog; high-potency GHS-R1a agonist with CD36-mediated cardioprotective activity in ischemia models.

Botanical plate of a young plant with its branching root system exposed
Plate 13Hexarelin
Primary Amino Acid Sequence His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂

Molecular Properties

Parameter Value
Chemical Name Hexarelin / Examorelin
Amino Acid Sequence His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂
Molecular Formula C₄₇H₅₈N₁₂O₆
Molecular Weight 887.04 g/mol
CAS Number 140703-51-1
Sequence Length 6 amino acids (synthetic hexapeptide with D-amino acids and methylation)
Receptor Target Growth Hormone Secretagogue Receptor 1a (GHS-R1a) / Ghrelin receptor; CD36

Physical Properties

Property Specification
Appearance White to off-white lyophilized powder
Solubility Soluble in water or aqueous buffer at ≥1 mg/mL; pH 5.0-7.0
pH (1% solution) 5.0 - 7.0
Hygroscopicity Low to moderate; standard desiccated storage
Solution Stability Stable at 4°C for 10-14 days; enhanced stability from D-amino acids and methylation

Analytical Specifications

Test Specification
HPLC Purity ≥98.0%
Mass Spectrometry Confirmed [M+H]⁺ = 887.04 ± 0.5 Da
Peptide Content ≥95% (by amino acid analysis)
Endotoxin Level <1.0 EU/mg
Acetate Content ≤5%
TFA Content ≤0.1%
Water Content ≤6% (Karl Fischer)

Storage Parameters

Condition Specification
Lyophilized Storage -20°C, desiccated, protected from light
Lyophilized Shelf Life 24-36 months when stored properly
Reconstituted Storage 2-8°C for up to 14 days; -20°C for up to 3 months
Analytical Stock Preparation Dissolve in sterile water or aqueous buffer with gentle vortexing for 30 seconds
Freeze-Thaw Cycles Tolerates up to 5 cycles; superior stability vs unmodified peptides
Light Sensitivity Moderate; store in amber vials recommended

In Vitro & Preclinical Model Concentrations

Literature summary of published study doses, routes, and schedules.
Experimental Model Published Concentration / Regimen Exposure Schedule Administration Context
In Vitro Pituitary Cell Assays 1-500 nM Acute stimulation (30 min to 2 hours) Culture media
Small Animal Models (Rodent) 50-300 μg/kg 1-2x daily SC, IV, or oral in rodent models
GH Secretion Studies (Rodent) 100-200 μg/kg Single dose or repeated for 7-28 days SC in rodent models
Cardioprotection Research (Rodent) 80-160 μg/kg Daily or BID for 1-4 weeks SC or IV in rodent models

Note: Concentrations and animal regimens summarized above are for research reference only. Hexarelin is intended strictly for laboratory research.

Key Research Studies

Literature summary of published study doses, routes, and schedules.
Year Study Focus Key Findings
1995 Discovery and potency characterization 2-methyl-D-Trp modification at position 2 increased GH-releasing potency 5-10x vs GHRP-6; demonstrated EC₅₀ of 0.05-0.5 nM (most potent synthetic GHRP); maintained stability and oral bioactivity
2000 Cardioprotective effects in ischemia models Hexarelin (80 μg/kg BID) reduced myocardial infarct size by 40-50% in animal models; effects partly GHS-R1a-independent; identified CD36 receptor interaction mediating cardiac protection
2006 Multi-organ protective effects Chronic hexarelin administration protected heart, kidney, liver from ischemia-reperfusion injury in animal models; anti-apoptotic effects via CD36 activation; reduced inflammatory cytokines 30-50%; GH-independent mechanisms identified
2011 Cortisol and prolactin co-secretion Hexarelin stimulation increased cortisol 2-3x and prolactin 3-5x alongside GH release; greatest ACTH/cortisol stimulation among GHRPs; limits therapeutic application but valuable research tool

Mechanism of Action

Biological Pathway Description
GHS-R1a Activation Most potent GHS-R1a agonist (Kd ~0.1-1 nM); 5-10x more potent than GHRP-6 for GH release; stimulates pituitary somatotrophs and hypothalamic GHRH neurons
GH/ACTH/Prolactin Secretion Strongest GH release among GHRPs; significant ACTH/cortisol co-stimulation (2-3x baseline); prolactin elevation (3-5x); peak GH at 15-30 minutes post-stimulus
CD36 Receptor Activation Binds CD36 (fatty acid translocase) with moderate affinity; mediates cardioprotection, anti-inflammatory effects, and anti-apoptotic actions independent of GH
Cardioprotection Direct cardiac effects via CD36; reduces oxidative stress; inhibits apoptosis; improves post-ischemic recovery; preserves contractile function in animal models
Half-Life 30-70 minutes (IV/SC); 2-methyl modification increases stability; oral bioavailability 5-10% (unusual for peptides)

Comparative Analysis: Hexarelin Potency

Compound GH Release EC₅₀ Relative Potency ACTH/Cortisol Effect
Hexarelin 0.05-0.5 nM 10x (reference) Strong (2-3x)
GHRP-2 0.1-1 nM 5-8x Moderate (1.5-2x)
GHRP-6 0.2-2 nM 5x Moderate (1.5-2x)
Ipamorelin 1-10 nM 1x Minimal (no increase)
GHRH (Sermorelin) 0.5-2 nM 1-2x None

Quality Control Parameters

Test Method Acceptance Criteria
Appearance (visual) White to off-white powder; no discoloration
2-Methyl-D-Trp Verification Position 2 modification confirmed by MS/MS; methylation >98%
Chiral Purity D-amino acids at positions 2 and 5 confirmed; >98% stereochemical purity
RP-HPLC (purity) Main peak ≥98.0%; no single impurity >0.5%
ESI-MS (identity) [M+H]⁺ = 887.04 ± 0.5 Da confirmed
Biological Activity ≥90% potency vs reference in GH release assay

Structure-Activity Relationship

Position Amino Acid Structural Role
1 L-His N-terminal; imidazole ring; similar to GHRP-6
2 D-2-Methyl-Trp KEY MODIFICATION: 2-methyl group increases potency 5-10x; D-configuration essential; enhanced receptor binding
3 L-Ala Conformational spacer
4 L-Trp Essential for GHS-R1a activation; indole ring critical
5 D-Phe Receptor selectivity; D-configuration prevents degradation
6 L-Lys-NH₂ C-terminal; positive charge; amidation required

Reported Biological Effects

Effect Category Observed Changes Timeframe
GH Secretion Peak GH increase 10-30x baseline (highest in GHRP class); occurs 15-30 min post-stimulus Acute (15-60 minutes)
ACTH/Cortisol Increased ACTH 2-3x, cortisol 2-3x (strongest among GHRPs); limits chronic application Acute (30-90 minutes)
Prolactin Elevated 3-5x baseline; dose-dependent response Acute (30-120 minutes)
Cardioprotection Reduced infarct size 40-50% in rodent models; improved ejection fraction; anti-apoptotic effects Hours to days
Appetite Moderate increase (+20-40%); less than GHRP-6 but present 1-3 hours

Regulatory & Compounding Status

Hexarelin (Examorelin) is an unapproved investigational research peptide. It is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for human or veterinary therapeutic use. This monograph is intended strictly for laboratory research.

External References

  1. Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86(4):1464-9. https://academic.oup.com/jcem/article/86/4/1464/2849229
  2. Muccioli G, et al. Growth hormone-releasing peptides and the cardiovascular system. Ann Endocrinol (Paris). 2000;61(1):27-31. https://pubmed.ncbi.nlm.nih.gov/10790589/
  3. National Center for Biotechnology Information. PubChem Compound Summary for Hexarelin. https://pubchem.ncbi.nlm.nih.gov/compound/Hexarelin